Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

13,982 total articles

MSCI Posts Higher Q4 Profit as Clients Flock to Indexes and Analytics

MSCI Posts Higher Q4 Profit as Clients Flock to Indexes and Analytics

MSCI reported stronger adjusted profit for the quarter ended December 31, driven by increased client spending on its index products and analytics services. Asset-based fees rose, lifting overall revenue, while operating costs grew more modestly as the company invested in staff and technology. Management highlighted continued multi-year growth in ad…

Wix Board Greenlights $2 Billion Buyback; Shares Jump on Announcement

Wix Board Greenlights $2 Billion Buyback; Shares Jump on Announcement

Wix.com Ltd. shares rose sharply after the company’s board approved a $2 billion share repurchase program spanning fiscal years 2026-2027. The authorization permits purchases of ordinary shares and convertible notes via open market and private transactions, to be funded by cash on hand, operating cash flow, or potentially new capital. The program i…

Birkenstock Seeks €1 Billion in New Revenue Over Next Three Years

Birkenstock Seeks €1 Billion in New Revenue Over Next Three Years

Birkenstock has set a target of generating 1 billion euros in incremental revenue across the next three years, aiming for annual top-line growth of 13%-15% at constant currencies. The company expects double-digit expansion in the Americas and EMEA, a doubling of its Asia-Pacific business, and adjusted EPS to grow about 200 basis points faster than …

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS Lowers Rating on Mobimo to Sell, Cites Peak Development Earnings in FY25

UBS cut its rating on Swiss property owner Mobimo to sell from neutral, saying the company’s development profits - a key earnings driver - should peak in fiscal 2025 and then decline as high-margin projects complete. The broker raised its 12-month price target to CHF330 from CHF308 after lowering its WACC and modestly raising revenue forecasts, but…

Palladyne AI Wins Air Force Research Laboratory Contract, Stock Jumps on Swarm Integration Work

Palladyne AI Wins Air Force Research Laboratory Contract, Stock Jumps on Swarm Integration Work

Palladyne AI Corp. (NASDAQ:PDYN) saw its shares climb 13% after the Air Force Research Laboratory granted the company a contract named HANGTIME. The program will deploy Palladyne’s SwarmOS™ platform to connect autonomous systems across multiple domains, integrating satellites for the first time and aiming to enable faster, coordinated decision-maki…

Eli Lilly secures up to $1.12 billion agreement with Seamless Therapeutics to pursue gene-editing treatments for hearing loss

Eli Lilly secures up to $1.12 billion agreement with Seamless Therapeutics to pursue gene-editing treatments for hearing loss

Eli Lilly has entered into a collaboration worth as much as $1.12 billion with Germany-based Seamless Therapeutics to develop and commercialize gene-editing therapies aimed at certain forms of hearing loss. The arrangement grants Lilly access to Seamless' proprietary enzyme platform, which engineers programmable recombinases designed to make large,…

UBS Downgrades Intershop to Neutral, Citing Limited Upside After Rally

UBS Downgrades Intershop to Neutral, Citing Limited Upside After Rally

UBS moved Intershop Holding AG (SIX:ISN) from a 'buy' to a 'neutral' rating while increasing its 12-month price target to CHF170. The brokerage says the stock's strong run has restored its valuation to historical norms, leaving scant upside from recent levels. UBS also trimmed revenue and adjusted EPS forecasts for fiscal 2025-27 and highlighted ti…

Eikon Therapeutics Seeks $908.2 Million Valuation in U.S. IPO

Eikon Therapeutics Seeks $908.2 Million Valuation in U.S. IPO

On Jan. 28, Eikon Therapeutics filed to pursue a U.S. initial public offering that would value the company at as much as $908.2 million and raise up to $317.7 million by selling 17.65 million shares at $16 to $18 apiece. The Millbrae, California-based drug developer is advancing a cancer pipeline led by EIK1001, being evaluated in combination with …